Navigation Links
Clinical Trial for the Treatment of Inflammatory Bowel Disease Begins at Tel Aviv Sourasky Medical Center
Date:7/21/2008

Anadis Ltd (ASX:ANX; OTC:ANDIY), a biopharmaceutical company focused on research, development and production of immune milk (colostrum)-derived polyclonal antibodies and other proteins to address major diseases, today announces the initiation of a clinical trial with top clinical scientists at Tel Aviv Sourasky Medical Center in Israel. The clinical trial will explore the efficacy of a formulation developed by Anadis to address the symptoms of Inflammatory Bowel Disease (IBD), a serious chronic condition effecting millions of persons annually.

MELBOURNE, Australia (Business Wire EON) July 21, 2008 -- About 4 million people worldwide suffer from Inflammatory Bowel Disease, split roughly evenly between the two manifestations of the disease: Crohn's disease (CD) and ulcerative colitis (UC). IBD is a relapsing / remitting chronic disease with gastrointestinal symptoms such as diarrhoea, rectal bleeding and abdominal pain.

The study is led by a leading Israeli Gastroenterologist, Professor Zamir Halpern, Deputy Director of Tel Aviv Sourasky Medical Center and Chief of the Center's Gastroenterology Institute, and by Professor Nachum Vaisman, Head of the Unit of Clinical Nutrition.

The first patients have already been recruited and have entered the trial which is expected be completed during 2009. The trial is designed as an open study being run to confirm and expand upon human clinical data obtained from a pilot study at St Vincent's Hospital in Melbourne, which ended recently. Anadis intends to launch its colostrum-derived product as a medical food or nutritional immediately following the Tel Aviv trial. Anadis will meet all regulatory requirements during the conduct of the trial itself.

In addition to the initiation of this IBD study, Anadis recently announced being awarded a VISTECH grant for another study, also to be conducted at Tel Aviv Souraski Medical Center, towards the development and commercialization of a product to address cancer-related mucositis. See "Anadis Awarded VISTECH grant for Clinical Trial of Polyclonal Antibodies for the Treatment of Cancer Related Mucositis" - Tuesday 1 July 2008."

Tel Aviv Sourasky Medical Center (TASMC) is one of the largest hospitals in Israel with 1100 beds and is responsible for providing specialty care to the Tel Aviv metropolitan area. It is a teaching and research center affiliated with the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Dr Oren Fuerst, VP Business development of Anadis stated, "This is another illustration of the successful collaboration between Anadis and the researchers at TASMC. The leveraging of Australian manufacturing and core research, with research and clinical studies in Israel will allow us to bring products to market faster and at lower costs than otherwise. Our current plans calls for commercialization of both the IBD and the mucositis products within less than 2 years, addressing two major gastrointestinal diseases using our core platform."

Read the full story at http://www.prweb.com/releases/tel_aviv/anadis/prweb1132164.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. Vertos Medical Inc. Presents Clinical Data of its MILD™ Procedure at the 5th Annual Innovative Techniques in Spine Surgery Conference in Los Cabos, Mexico
2. North Carolinas Center For Advanced Medicine & Clinical Research Celebrates Opening of New LKN Medical Spa and Rejuvenation Center
3. Brain cancer study: Magnitude of post-vaccine immune response linked to clinical outcomes
4. Northwestern Memorial Among Americas Best Hospitals in 10 Clinical Specialties According to U.S. News 2008 Rankings
5. Dr. Daniel Von Hoff Discusses "The Complete Phase Ib," A Clinical Trial Design Offering Faster Drug Development, Economies of Scale and Improved Therapeutic Benefit
6. Termination of IS Clinical From Distributing PhytoCeuticals Formulas
7. Dr. Howard Epstein Joins Blue Cross as Medical Director for Commercial Operations and Clinical Design
8. Award-Winning Massachusetts Hospital Selects MedQuist Enterprise Technology for Clinical Documentation and Speech Recognition
9. Clinical Launch of Innovative Cloth Sleep Apnea Mask Creates Buzz at Sleep Conference
10. New clinical trial for patients with asbestos-associated lung cancer
11. Because of Its Ability to Generate Higher Total Sales in the United States and Europe, Lucentis Will Earn Clinical Gold Standard Status by 2011 for the Treatment of Diabetic Retinopathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... August 17, 2017 , ... Aeroflow Healthcare today ... recognizing America’s fastest growing private companies. Inc. magazine ranked Aeroflow Healthcare #2450 on ... , The Inc. 5000 represents the most comprehensive study of American ...
(Date:8/17/2017)... ... August 17, 2017 , ... SeQuel Response announced ... multichannel growth agency among the fastest-growing private companies in the U.S., putting it in ... companies that have applied to the Inc. 5000 over the years, only ...
(Date:8/17/2017)... ... August 17, 2017 , ... With the introduction of new ... a number of changes to the smartwatch market. As of June 2017, nearly nine ... from the six months prior. Additionally, according to latest WEAR Report Industry Overview and ...
(Date:8/17/2017)... ... August 17, 2017 , ... Inc. Magazine Unveils 36th Annual List ... with Three-Year Sales Growth of 3,004.8% , NEW YORK, August 16, 2017 – Inc. ... most prestigious ranking of the nation's fastest-growing private companies. The list represents a unique ...
(Date:8/17/2017)... ... August 17, 2017 , ... Advice Media, the industry leader in digital marketing for medical practices, ... and has been included in the Inc. 5000 for the second time in two years. ... in the Inc. 5000 rankings for the second year in a row. It’s extremely difficult ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... Aug. 2, 2017  Life Flight Network and PeaceHealth Oregon ... improves patient care and operational efficiency for patients at hospitals ... , Cottage Grove , and ... PeaceHealth and Life Flight Network work collaboratively to move patients ... or when a time sensitive emergency exists. ...
(Date:8/1/2017)... , Aug. 1, 2017   CerSci Therapeutics , ... Dallas, Texas , has received notice from the ... Institutes of Health (NIH) that it has been awarded ... totaling over $650,000 in 2017 with an additional $1,000,000 ... Investigational New Drug application of their lead non-opioid drug ...
(Date:7/31/2017)... Three Tru-D SmartUVC robots have arrived at Brian ... . Tru-D, short for "Total Room Ultraviolet Disinfection," is a 5-foot-5 germ-killing ... services (ES) professional cleans the area with traditional cleaning protocols. ... Tru-D fights germs at Army ... "Although the BAACH has a very low infection ...
Breaking Medicine Technology: